Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 4, 2007, Pages 509-514

  Bruynzeel, Anna M E ^a   Vormer Bonne, Suzanne ^a   Bast, Aalt ^c   Niessen, Hans W M ^a,b   Van Der Vijgh, Wim J F ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardioprotection; Cardiotoxicity; Doxorubicin; Long term follow up; MonoHER; Monohydroxyethylrutoside

Indexed keywords

DOXORUBICIN; FLAVONOID; MONOXERUTIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG FATALITY; DYSPNEA; FOLLOW UP; HEART FAILURE; HEART INJURY; HEART PROTECTION; HISTOLOGY; MALE; MORTALITY; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; HEART DISEASES; HYDROXYETHYLRUTOSIDE; MALE; MICE; MICE, INBRED BALB C; MYOCARDIUM; TIME; WEIGHT LOSS;

EID: 34447500505     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0395-2     Document Type: Article

References (26)

1. Billingham ME, Mason JW, Bristow MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62(6):865-872
2. Boots AW, Balk JM, Bast A, Haenen GRMM (2005) The reversibility of the glutathionyl-quercetin adduct spreads oxidized quercetin-induced toxicity. Biochem Biophys Res Comm 338:923-929
3. Breinholt VM, Mølck AM, Svendsen GW, Daneshvar B, Vinggaard AM, Poulsen M, Dragsted LO (2003) Effects of dietary antioxidants and 2-amino-3-methylimidazo[4,5-f]- quinoline (IQ) on preneoplastic lesions and on oxidative damage, hormonal status, and detoxification capacity in the rat. Food Chem Toxicol 41:1315-1323
4. Bruynzeel AME, Mul PNN, Berkhof J, Bast A, Niessen HWM, van der Vijgh WJF (2006) The influence of the time-interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemother Pharmacol 58(5):699-702
5. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracyclin cardiotoxicity in children and adults. Semin Oncol 25(suppl 10):72-85
6. Haenen GRMM, Jansen FP, Bast A (1993) The antioxidant properties of five O- (beta-hydroxyethyl) rutosides of the flavonoid mixture Venoruton. Phlebology Suppl 1:10-17
7. Hibatallah J, Carduner C, Poelman MC (1999) In-vivo and in-vitro assessment of free radical scavenger activity of Ginkgo flavone glycosides at high concentration. J Pharm Pharmacol 51(12):1435-1440
8. Horenstein MS, Vander Heide RS, L'Ecuyer TJ (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metabol 71:436-444
9. Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M (2000) Anthracycline-induced cardiotoxicity. Acta Medica 43(3):75-82
10. Iarussi D, Indolfi P, Galderisi M, Bossone E (2000) Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 25(7):676-688
11. Kremer LCM, van Dalen EC, Offringa M, Ottenkamp J, Voute PA (2001) Anthracyclin-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191-196
12. Langebrake C, Reinhardt D, Ritter J (2002) Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf 25(15):1057-1077
13. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314
14. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Eng J Med 324:808-815
15. Niering P, Michels G, Wätjen W, Ohler S, Steffan B, Chovolou Y et al. (2005) Protective and detrimental effects of kaempferol in rat H4IIE cells: implication of oxidative stress and apoptosis. Toxicol Appl Pharmacol 209:114-122
16. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. New Eng J Med 339(13):900-904
17. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID (2003) Late anthracyclin cardiotoxicity after childhood cancer. Cancer 97(8):1991-1998
18. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L (2001) Cardiac toxicity 4 to 20 years after completing anthracyclin therapy. JAMA 266(12):1672-1677
19. Sugihara N, Arakawa T, Ohnishi M, Furuno K (1999) Anti- and pro-oxidative effects of flavonoids on metal-induced lipid hydroperoxide-dependent lipid peroxidation in cultured hepatocytes loaded with alpha-linolenic acid. Free Radic Biol Med 27(11-12):1313-1323
20. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin. Cancer 97(11):2869-2879
21. Thomson AR, Mortensen A, Breinholt VM, Lindecrona RH, Penalvo JL, Sorensen IK (2005). Influence of Prevastein, an isoflavone-rich soy product, on mammary gland development and tumorigenesis in Tg.NK (MMTV/c-neu) mice. Nutr Cancer 52(2):176-188
22. Van Acker SABE, Towart R, Husken BCP, de Jong J, van der Vijgh WJF, Bast A (1993) The protective effect of Venoruton and its constituents on acute doxorubicin-induced cardiotoxicity. Phlebology Suppl 1:31-32
23. Van Acker SABE, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, Kramer K, Bast A, van der Vijgh WJF (1997) Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3(10):1747-1754
24. Van Acker FAA, van Acker SABE, Kramer K, Haenen GRMM, Bast A, van der Vijgh WJF (2000) 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6(4):1337-1341
25. Vermeulen EG, Niessen HW, Bogels M, Stehouwer CD, Rauwerda JA, v Hinsbergh VW (2001) Decreased smooth muscle cell/extracellular matrix ratio of femoral artery in patients with atherosclerosis and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 21:573-577
26. Xu MF, Tang PL, Oian ZM, Ashraf M (2001) Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci 68(8):889-901